Regarding the eGFR data in the CKD sub-study, I think CitySlicker nailed it with #3:

"eGFR was improved but they are keeping quiet about despite the impact on share value. The only reason I can think of here is that it is going to be presented at a meeting or published in a paper soon and there is a prior agreement with investigators not to go public before then and/or an embargo imposed by the journal or congress."

Sub-studies like the CKD and Cognition BETonMACE sub-studies are not required to be presented and/or published along with the primary and secondary BETonMACE endpoints at AHA. This is why the Cognition sub-study presentation at CTAD came later after AHA. Same think for CKD sub-study. 

The timing of American Heart Association (AHA) and American Society for Nephrology (ASN) Kidney Week was not conducive to presentation of BETonMACE CKD sub-study at a major meeting; ASN happened Nov 5-10, which was prior to AHA Nov 16-18. In my opinion, first presentation of any BETonMACE data had to be at AHA, and AHA embargo and timing of ASN prevented CKD sub-study from being presented earlier at ASN.

There have not been any major kidney/renal clinical meetings since ASN. Therefore, H1 2020 is ripe for the presentation of the CKD sub-study data. And also keep in mind that a top-line news release could still be issued regarding the CKD sub-study prior to whatever meeting they present at. This news release would likely lack detailed data in order to prevent embargo violation.

I still think National Kidney Foundation 2020 at end of March in New Orleans is a likely candidate. Full program has not been release yet.

https://www.kidney.org/spring-clinical

BDAZ